Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46-61%) and 73% (67-80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33-55%] vs 63% [54-73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1.

Authors

Institutions

Publication Details

Journal
Blood Cancer Journal
Published
2025-04-03
DOI
https://doi.org/10.1038/s41408-025-01259-z
Citations
26
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
46.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Saad Z. Usmani, Efstathios Kastritis, Chris Lau, Brian G.M. Durie et al.
26 citations
Blood Cancer Journal
Multiple Myeloma Research and Treatments
46.02
article

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Saad Z. Usmani, Efstathios Kastritis, Chris Lau, Brian G.M. Durie, Magdalena Corona, Saurabh Chhabra, Meletios Athanasios Dimopoulos, Joaquín Martínez‐López, Sikander Ailawadhi, Ricardo Parrondo, Hira S. Mian, Thomas G. Martin, Sireesha Asoori, Catriona Mactier, Kwee Yong, Chiung‐Yu Huang, Adolfo Sáez, Rakesh Popat, Radhika Bansal, Carlyn Rose C. Tan, Despina Fotiou, Yi Lin, Larissa Brunaldi, Andre De Menezes Silva Corraes
article en
26 citations

Abstract

Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46-61%) and 73% (67-80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33-55%] vs 63% [54-73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1.

Blood Cancer JournalVol. 15(1)
Cedars-Sinai Medical Center (US), Memorial Sloan Kettering Cancer Center (US), University of California, San Francisco (US), National and Kapodistrian University of Athens (GR), Martin University (US), WinnMed (US), Research Institute Hospital 12 de Octubre (ES), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US), University College London (GB), McMaster University (CA)
Bristol-Myers Squibb Foundation, Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Gilead Sciences, Celgene, Memorial Sloan-Kettering Cancer Center, Array BioPharma, Regeneron Pharmaceuticals, BeiGene, SkylineDx, Ascentage Pharma, National Institute for Health and Care Research, University College London, Swedish Orphan Biovitrum, National Institutes of Health, Genentech, Kite Pharma, Pharmacyclics, National Cancer Institute, Cilag
Partnerships for the goals
Openalex Percentile: Top 0%
Multiple Myeloma Research and Treatments
46.02
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.